arrow
M

Michele Caruso

nerviano medical sciences s.r.l
H指数:29
被引数:3,403

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report

激素受体阳性/HER2阴性转移性乳腺癌的演变格局(EVOLVE):一项意大利Delphi共识报告

2025-06-060
OA
Predictors of mastectomy in breast cancer patients with complete remission of primary tumor after neoadjuvant therapy: A retrospective study

新辅助治疗后原发肿瘤完全缓解的乳腺癌患者行乳房切除术的预测因素: 一项回顾性研究

EJSO
IF2.9
2024-12-0110
OAAI
BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib plus letrozole and on second-line treatment with alpelisib plus fulvestrant
2020-09-010
OAAI
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

甲磺酸Eribulin作为转移性乳腺癌患者的三线治疗 (VESPRY): 一项前瞻性,多中心,观察性研究

2019-12-1911
OAAI
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
BREAST
IF7.9
2018-10-0146
PREAI
Thienoindoles: New highly promising agents for antibody-drug conjugates generation
2018-07-012
PRE
Ado-trastuzumab emtansine (T-DM1) in HER2+advanced breast cancer patients: does pretreatment with pertuzumab matter?

Ado-trastuzumab emtansine (T-DM1) 在HER2晚期乳腺癌患者中的应用: 帕妥珠单抗预处理是否重要?

2017-11-2823
PREAI
Tumor Targeting with an isoDGR-Drug Conjugate
2017-05-2618
OAAI